NASDAQ : PBM
Psyence Biomedical Ltd. — Key statistics
Healthcare · Biotechnology · Canada
Last price 3.61 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.77M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 12.63M |
| Enterprise Value | 5.18M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.81M |
| Shares Outstanding | 3.81M |
| Shares Change (YoY) | +1,688.07% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.66% |
| Owned by Institutions (%) | 14.56% |
| Float | 1.11M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 14.62 |
| Quick Ratio | 12.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -655.06 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -58.62% |
| Return on Assets (ROA) | -31.33% |
| Return on Invested Capital (ROIC) | -32.95% |
| Return on Capital Employed (ROCE) | -36.81% |
| Weighted Average Cost of Capital (WACC) | 13.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$578,035 |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.69 |
| 52-Week Price Change | -83.90% |
| 50-Day Moving Average | 4.83 |
| 200-Day Moving Average | 3.99 |
| Relative Strength Index (RSI) | 35.13 |
| Average Volume (20 Days) | 54,962 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20,292 |
| Short Previous Month | 26,839 |
| Short % of Shares Out | 0.53% |
| Short % of Float | 1.83% |
| Short Ratio (days to cover) | 0.26 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.24M |
| Pretax Income | -6.94M |
| Net Income | -6.94M |
| EBITDA | -6.23M |
| EBIT | -6.24M |
| Earnings Per Share (EPS) | -$12.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.44M |
| Total Debt | n/a |
| Net Cash | 7.44M |
| Net Cash Per Share | $1.95 |
| Equity (Book Value) | 16.94M |
| Book Value Per Share | 7.39 |
| Working Capital | 8.49M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.14M |
| Capital Expenditures | -229 |
| Depreciation & Amortization | 5,266 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.14M |
| FCF Per Share | -$2.13 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,688.07% |
| Shareholder Yield | -1,688.07% |
| Earnings Yield | -379.44% |
| FCF Yield | -64.50% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:6.25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |